Anyone who has been involved in the medical field knows that cancer treatment is a highly complex aspect of medicine, and one that is growing and changing continually. New forms of treatment are being developed continually, but for anyone who is dealing with the illness, the reality is that effective treatment can’t come fast enough. All of this is why tech developer and entrepreneur Eric Lefkovsky (the visionary behind Groupon, Tempus Labs, Echo Global Logistics and more) is so passionate about putting his tech savvy and philanthropic expertise into helping speed up the treatment process for those in need.
Aligning The Tech Savvy of Tempus to Treatment
Lefkovsky is the CEO and also founder of Tempus Labs, which today is one of Chicago’s top health labs. One of the jobs of Tempus is to store vast amounts of data taken from patients in cancer treatment. It’s Lefkovsky’s view, however, that right now there is breakdown in communication between this stored molecular data, and the physicians who need access to it in order to develop effective patient care regimes. When patient’s need care, time is of the essence, especially when we are talking about cancer treatment. This is why Lefkovsky is making it a priority for Tempus to be part of the solution, as far as getting physicians greater access to the information that is critical to providing a top level of care, fast.
Developing an Information Platform
Tempus has been created to collect gene sequencing information and provide data analysis. Lefkovsky wants to create a platform that would act as an educational center for doctors that need patient data. This platform would integrate patient data along with the clinical information needed to dictate treatment plans. This would be a personalized patient care model that could provide a revolutionary advance in providing access to cancer treatment.
Lefkovsky’s plans are certainly ambitious, but if his history tells us anything, it’s that once a goal has been set, he will meet it, all of which is great news for medical research, to be sure.
Eric Lefkovsky info: lefkofskyfoundation.com/about-eric-lefkofsky/
Just last September, Cancer Treatment Centers of America made health headlines by providing free and reduced cost prostate screens for promotion of preventative health tests now recommended for men. This well known cancer organization partnered with other interested in helping groups to provide this valuable health service. Many men die to prostate cancer every year. Many others are limited sexually and have frequent difficulty with urination. Often, the prostate becomes enlarged as a man ages. Prostate cancer should be ruled out early on to prevent unnecessary deaths and suffering. Prostate cancer can be treated effectively, relatively easily and often successfully when the diagnosis is made early in the disease process.
Cancer Treatment Centers of America has been a strong supporter of cancer screening as part of their preventative health promotion efforts. They treat adult men and women diagnosed with cancer, and this organization is invested in ongoing clinical and cancer research trials to find more treatments and cure many various cancer forms. Prostate cancer is a high occurring cancer for men. The number of cases rises as males get older. These gentlemen should seek medical treatment with any signs of urination or sex problems. Safe and simple prostate screens can detect prostate cancer early even if the individual isn’t noticing any problem symptoms.
With attention on preventative health these days, more people and their physicians are open and supportive of preventative health measures. Cancer Treatment Centers of America is continuing to provide essential cancer treatments and preventative or early diagnostic cancer tests and screens. These tests are not uncomfortable or time consuming. Every man should speak with their family doctor about this devastating disease. There are things that can be done to help slow and prevent the occurrence of this fast spreading cancer. Find out more online or call CTCA.
Data- driven precision medicine has been touted as the next frontier in oncology. Every day, millions of people across the globe are diagnosed with different types of cancer. The disease has become one of the biggest contributors to high mortality rates in the modern society. With more and more cases of cancer being reported, doctors are finding themselves in a situation where they need to comb through mountains of data for them to recommend the best therapies.
Eric Lefkosfky became aware of the challenges that oncologists faced in their work when he took his wife for treatment. A loved one to the businessman had been diagnosed with breast cancer, and she needed personalized therapies. It was at this moment that Eric discovered the limited amount of data that is available for oncologists to draw analyses and trends before they can recommend treatment. From this realization, Eric decided to come up with a technological solution that will avail genomic and therapeutic data from cancer patients so that doctors can draw patterns that will enable them to administer personalized cancer treatment solutions and learn more about Eric.
Tempus is a company that samples, collects and aggregates data from a cancer patient with the aim of drawing analytics that will help doctors in medical research to come up with more effective therapies for cancer. For a long time, personalized healthcare has been a preserve of the elite. Tempus is working to ensure that precision medicine can be made affordable to the average man. Unlike the existing cancer therapies that attack the cancer cells, Eric Lefkofsky’s company intends to come up with solutions that fight the disease at the molecular level.
Eric Lefkofsky was brought up in Southfield, Michigan. The entrepreneur graduated from the renowned University of Michigan. He earned his degree in laws from the Law School of the same institution. The business leader has also lived in Chicago for several years. He is best known in the corporate circles as the co-founder of Tempus and Groupon.
Apart from being committed to the advancement of research in medicine, Eric Lefkofsky is also involved in philanthropy. The seasoned entrepreneur has also been successful in the halls of academia. He currently holds the position of adjunct professor at the Business School of the University of Chicago and more information click here.
More Visit: http://chicago.curbed.com/2015/1/6/10005148/groupon-ceo-eric-lefkofsky-the-man-behind-195m-home-sale
When Eric Lofkosfky left Groupon, he began building up the newly launched firm, Tempus. Tempus is a modern day cancer treatment facility that uses high-tech devices to diagnose and treat cancer. Tempus’ medical practitioners use real-time and customized data–based therapy machines to analyze each patient’s genetic makeup. They then use the results to determine the best molecular therapies for the particular cancer type ailing the candidate. The technology helps patients understand a patient’s tumor better to create a most suitable medication using massive amounts of statistical genomic data. The company separated itself from its parent company LightBank, which is also owned by Eric. Eric is currently serving as Tempus’ president and believes that the firm can develop next breakthrough in medicine world.
On July 18th, 2016, Eric wrote about how data collection and artificial intelligence propel the society forward in medicine. He explained the various ways that health care has reached milestones in developing new technology. In 2003, Tempus produced the first human genome with over 100 million dollars. After only 13 years they, processed the same procedure with only 5000 dollars. He estimates that in a few more years, it will be available for just a few hundred dollars. The system allows physicians to tailor the necessary treatments medicine rations for all cancers. Currently, Tempus has an employee capacity of 29, including the former director of products At HighGround, Hunter Lane and Lightbank’s former vice president, Ryan Fukushima.
Eric and his wife Liz are regular donors to the cancer research treatment movement through their organization Lofkosfky Family Foundation. In November 2016, they contributed 1 million dollars to the Robert Lurie Comprehensive Cancer Center of the Northwestern University. In October of the same year, they donated $500,000 to the development of immunotherapy gastric cancer at the Stanford University. They contributed 1.2 million dollars to cancer research at the University of Michigan. The New York Weill Cornell Medicine Foundation received $250,000 from the couple to treat breast cancer. Eric and his wife are members of The Giving Pledge and have a pledge to donate half of their wealth to philanthropy at the end of their lifetimes.
for more info: www.tempus.com/about-us/